Gaining insight into these pathomechanisms has helped to improve the clinical management of MuSK-MG, which has evolved from an AChR-antibody negative, severe, and difficult-to-treat disease to a MuSK-antibody positive condition with a beneficial outcome in most cases. Here, MUSK is linked to myasthenia gravis.